Moderna secures $750 million from Blackstone to develop mRNA flu vaccines.

Funding aims to offset Moderna's declining COVID-19 vaccine sales.

Investment also bolsters Moderna's cancer and RSV vaccine research.

Moderna's CFO, James Mock, sees partnership as a means to diversify and mitigate financial risks.

The deal grants Blackstone commercial milestone payments and royalties from flu vaccine sales.

Moderna's stock rises following the announcement of the deal.

The collaboration with Blackstone underscores a shared dedication to biopharmaceutical innovation.